Comment: POLO III trial for metastatic pancreatic cancer

Bookmark and Share
Published: 24 Jun 2019
Views: 2666
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Prof Heinz-Josef Lenz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the POLO III trail, and his opinion on the findings.

He explains an outline of the trial, including some of. the many benefits to using a PARP inhibitor.

This programme has been supported by an unrestricted educational grant from Pfizer.